As the world’s biggest clinical cancer research conference, ASCO is always a very significant event on Immutep’s calendar. This year was extra special as we announced new and exciting clinical results from Part A of our Phase II TACTI-002 trial of our lead product candidate, eftilagimod alpha, or efti.
This Part of the trial is evaluating efti when given in combination with our collaboration partner MSD’s antiPD-1 therapy KEYTRUDA® (pembrolizumab) in 114 patients with 1st line non-small cell lung cancer (NSCLC).
To view the presentation, download the attached PDF.
Download this document
